- Home
- KFS vs PROK Comparison
KFS vs PROK Comparison
Compare KFS & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KFS | PROK |
|---|---|---|
| Founded | 1989 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 330.1M | 296.8M |
| IPO Year | 2013 | 2021 |
Fundamental Metrics
Financial Performance| Metric | KFS | PROK |
|---|---|---|
| Price | $11.85 | $1.88 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $7.40 |
| AVG Volume (30 Days) | 74.8K | ★ 1.0M |
| Earning Date | 05-11-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $134,996,000.00 | $893,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 23.42 | ★ 1075.00 |
| 52 Week Low | $8.27 | $0.54 |
| 52 Week High | $16.80 | $7.13 |
Technical Indicators
Market Signals| Indicator | KFS | PROK |
|---|---|---|
| Relative Strength Index (RSI) | 56.19 | 44.31 |
| Support Level | $11.73 | $1.71 |
| Resistance Level | $12.13 | $2.58 |
| Average True Range (ATR) | 0.37 | 0.12 |
| MACD | 0.05 | 0.01 |
| Stochastic Oscillator | 55.36 | 13.89 |
Price Performance
Historical ComparisonAbout KFS Kingsway Financial Services Inc. (DE)
Kingsway Financial Services Inc through subsidiaries operates in the extended warranty and business services industries in the United States. The company operates through segments namely, Extended Warranty and Kingsway Search Xcelerator. The Extended Warranty segment provides after-market vehicle protection services distributed by credit unions. The company generates maximum revenue from the Extended Warranty segment in the form of Service fee and commission income.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.